1. Home
  2. KULR vs CRDL Comparison

KULR vs CRDL Comparison

Compare KULR & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KULR Technology Group Inc.

KULR

KULR Technology Group Inc.

HOLD

Current Price

$2.62

Market Cap

116.6M

Sector

Technology

ML Signal

HOLD

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$1.16

Market Cap

132.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KULR
CRDL
Founded
2013
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
116.6M
132.6M
IPO Year
2016
2017

Fundamental Metrics

Financial Performance
Metric
KULR
CRDL
Price
$2.62
$1.16
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$8.50
AVG Volume (30 Days)
1.4M
820.7K
Earning Date
05-15-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$1,274,028.00
N/A
Revenue This Year
$123.93
N/A
Revenue Next Year
$63.38
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.94
$0.88
52 Week High
$6.30
$1.71

Technical Indicators

Market Signals
Indicator
KULR
CRDL
Relative Strength Index (RSI) 36.30 52.45
Support Level $2.05 $0.95
Resistance Level $2.76 $1.38
Average True Range (ATR) 0.24 0.09
MACD -0.04 0.01
Stochastic Oscillator 10.60 57.38

Price Performance

Historical Comparison
KULR
CRDL

About KULR KULR Technology Group Inc.

KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices. The Company operated two segments -EMP and Mining of Digital Assets.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Share on Social Networks: